Skip to content

Transcutaneous electrical nerve stimulation for pain analgesia in lung cancer patients

Clinical trial of pain analgesia based on psycho-physical methods in lung cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016004
Enrollment
Unknown
Registered
2018-05-05
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

conventional therapy group:analgesic drugs with proper dose
TENS with drug therapy group:TENS with drug therapy
sham TENS with drug therapy:sham TENS+drug

Sponsors

Institute of Cancer Prevention and Treatment, Shandong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Postoperative pain group Patients with moderate/sever pain (pain ratings on 0-10 visual analogue scale = 4) and good compliance after surgery anesthesia or removing the automatic analgesic pump will be recruited. Particularly, inpatients need to be affirmed by their doctor that no adverse events would happen to affect the healing of their wounds. 2. Chronic pain group With moderate/sever pain (pain ratings on 0-10 visual analogue scale = 4) and good compliance; The estimated lifetime = 6 months; Pain can be relieved after taking analgesics with a rating of 0-10 visual analogue scale = 2 one week before participation; No radiotherapy( if patients are accepting radiotherapy, their pain sites should be non-irradiated and confirmed by their doctor that no analgesic effects are produced by the radiotherapy); Patients who meet the above criteria will be recruited in the Chronic pain group; All patients should give their written informed consent before participation.

Exclusion criteria

Exclusion criteria: Patients with the following conditions will be excluded from the trial: 1. Respiratory inhibition, airway obstruction or tissue hypoxia, heart disease, nervous system disease, abnormal cognitive function, or mental disease; 2. BMI < 18.5 or = 28; 3. Attending other clinical trial at the same time.

Design outcomes

Primary

MeasureTime frame
analgesic drug dose;pain intensity;pain relief;

Secondary

MeasureTime frame
Quality of Life;anxiety/depressive level;cortisol levels in blood;side effect;

Contacts

Public ContactDianmin Sun

Institute of Cancer Prevention and Treatment, Shandong

sundianmin@sdu.edu.cn+86 18560129779

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026